We bought shares of Royalty Pharma plc (NASDAQ: RPRX) to both earn Alpha and as a stable anchor stock!
Royalty Pharma (RPRX) has undertaken several significant initiatives:
Financial Transactions and Investments:
November 4, 2024: Entered into a $350 million synthetic royalty funding agreement with Syndax Pharmaceuticals, based on U.S. net sales of Niktimvo (axatilimab-csfr).
November 7, 2024: Agreed to acquire a synthetic royalty on U.S. sales of Geron Corporation’s Rytelo for $125 million in cash upfront.
January 29, 2025: Monetized the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash.
Corporate Developments:
- January 10, 2025: Announced the acquisition of its external manager and initiated a $3 billion share repurchase program, marking a transformative step in the company's evolution.
Financial Performance:
November 6, 2024: Reported third-quarter 2024 financial results and raised full-year 2024 guidance for Portfolio Receipts.
January 28, 2025: Scheduled to announce fourth-quarter and full-year 2024 financial results on February 11, 2025.
Dividend Announcement:
- January 9, 2025: Declared a first-quarter 2025 dividend of $0.22 per Class A ordinary share, reflecting a 5% increase over the previous quarter's dividend.
These actions underscore Royalty Pharma's commitment to strategic investments and shareholder value enhancement.
